April 2025
BiomX’s phage therapy shows promise in Phase II diabetic foot infections study
BX211, Phage Therapy, DFO
Corcept planning US, EU submissions for cortisol modulator after ovarian cancer win
Corcept, 130-nm albumin-bound paclitaxel
Transcend’s neuroplastogen posts positive mid-stage results in PTSD
TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5
ACC25: Merck & Co.’s Winrevair reduces mortality in most severe PAH patients
Pulmonary arterial hypertension, Winrevair, Severe (severity modifier), Mortality Vital Statistics
Solbinsiran: Eli Lilly’s Promising ANGPTL3 Inhibitor for Lipid Management
ANGPTL3 inhibition, solbinsiran, dyslipidemia, lipid reduction, siRNA therapy